The iPSC manufacturing cost case.
Allogeneic iPSC manufacturing vs. autologous models: what the cost structure means for your program.
Download the Analysis
The iPSC-first CDMO.
Making cell therapies mainstream for Japan’s iPSC-Derived Cell Therapy and Regenerative Medicine programs.
Cellistic brings 15 years of exclusive iPSC focus to your program. EMA-certified facility, PMDA-compliant processes, and pre-established platforms designed to get you to clinic faster. We work alongside your team from cell line development through GMP supply.
15+
Years of exclusive iPSC focus
32,000
Square feet of GMP manufacturing space
100L
Stirred-tank bioreactor scale
EMA-certified facility, FDA & PMDA compliant
Secure clear IP positioning and licensing framework
Pre-established technology platforms
Manufacturing for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell
In December 2024, Cellistic entered a process development and manufacturing agreement with BrightPath Bio, Inc., a Tokyo Stock Exchange-listed developer of iPSC-derived NKT cell therapies. The collaboration includes the use of Cellistic's Echo™ platform to enable GMP-compliant, clinical-scale manufacturing for a Phase 1 trial of iPSC-derived BCMA-targeting CAR-NKT cells for multiple myeloma.
BrightPath Bio selected Cellistic for its bioreactor-based differentiation capability, GMP compliance, and established process for iPSC-to-NK cell manufacturing.
We are delighted to partner with Cellistic, which has the most experience in culturing iPS cells using 3D bioreactors. This collaboration with Cellistic allows us to leverage their state-of-the-art development and manufacturing capabilities to accelerate the development of our BCMA CAR-NKT product.
iPSC CDMO services from cell line development to GMP supply.
End-to-end iPSC development and manufacturing, backed by proprietary platforms built for allogeneic cell therapy at clinical and commercial scale.
CDMO Services
- Cell Line Development Reprogramming, gene editing, and GMP cell banking via the Pulse™ platform
- Process & Analytical Development Process design, scale-up, and assay development aligned to your CMC strategy
- Master Cell Banking MCB and WCB generation under GMP with deep characterization and QA oversight
- GMP Manufacturing Clinical and commercial manufacturing in EMA-certified, PMDA-compliant suites
- QC Testing & Release In-house release testing: identity, purity, sterility, genetic stability, viral safety
- Regulatory Support CMC documentation, QP batch certification, worldwide export under MIA/GMP Certificate
Learn more
Technology Platforms
-
Pulse™ Cell Line Development Platform
From donor to cell engineered GMP Master Cell Bank, leveraging STAR-CRISPR™ proprietary gene editing technology and Allo Chassis™ immune-cloaked cell lines
-
Cellistic's Echo™ Differentiation and scalable GMP Manufacturing Platform
Pre-established stirred-tank bioreactor-based processes for clinical production
iPSC CDMO services from cell line development to GMP supply.
Cellistic supports iPSC-derived cell therapy programs across the full development pathway, from cell line development through to GMP drug product release. Programs can engage at any stage, with Pulse covering cell line development and Cellistic Echo covering differentiation and manufacturing.
Pulse™: iPSC Cell Line Development
Cellistic Echo™: Cell Therapy Manufacturing
Donor
Reprogramming
Cell Type
HiPSC Clone
Gene-Editing
Engineered hiPSC (pre-bank)
Master Cell Bank
WCB generation (optional)
Differentiation
Fill & Finish
Release of DP
Case study: Scalable manufacturing of iPSC-derived cardiomyocytes
Highlights a scalable bioprocess for generating high-purity, ventricular-like cells under chemically defined conditions.
Read the case study
How to partner with Cellistic.
Flexible entry, proven path. Whether you're at concept stage or mid-development, we adapt to your programme's needs and challenges — from R&D through GMP supply.
Model 1
Product development using platforms
Co-develop your iPSC-derived therapy using Cellistic's Pulse™ and Echo™ platforms, from cell line development through clinical manufacturing.
Model 2
CDMO services
Transfer your existing process or start from scratch. Cell line development, process and analytical development, GMP manufacturing, and regulatory support under one roof.
Model 3
Technology licensing
Access Cellistic's IP — including STAR-CRISPR™ and Allo Chassis™ — standalone or bundled, with a clear line of sight to commercial terms.
Vision and Expertise
Our CEO and CTO shape the long-term vision that guides our work, drawing on longstanding experience across iPSC science, manufacturing, and cell therapy development.
Jason Conner
Chief Executive Officer
Stefan Braam, PhD
Chief Technical Officer